Australian biotechnology company, Bionomics Limited (ASX: BNO), announced today that it has completed the GMP (Good Manufacturing Practices) synthesis of its promising new cancer drug candidate, BNC105. Bionomics is now using this material for formal toxicology studies, the final stage of testing prior to anticipated human clinical trials. The same batch will also be used for clinical trials.
